Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

[7] Increased autoimmunity appears to be primarily the result of the combined effects of the reduction in naive T cells (produced by thymus involution) in concert with an activation of self ...

Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...